Cancer Treatment Centers of America (CTCA) researchers present four studies on lung cancer treatment and survival, including a protein linked to malaria as a potential biomarker and genomic sequencing to accelerate therapeutics development.
Dr. Glen Weiss presents five innovative cancer studies at ASCO, including liquid biopsies for predicting treatment improvements and promising results with avelumab against recurrent-refractory ovarian cancer. Brigatinib shows substantial antitumor activity in ALK non-small cell lung cancer patients.
The Cancer Treatment Centers of America is hosting its second Annual New Treatments in Oncology (ANTO) conference on March 5 at the W Scottsdale hotel. The event will feature leading oncologists discussing recent advances and innovations in cancer research, treatment options, and patient care.
A recent study published in PLOS ONE found that statins increased overall survival among late-stage SCLC patients, while other medications showed no benefit. Radiotherapy was also identified as an independent predictor of survival.
A clinical trial using Pembrolizumab plus chemotherapy found the treatment to be safe for patients with advanced small cell and non-small cell lung cancer. The study, led by Dr. Glen Weiss, presented initial results from 12 lung cancer patients enrolled in the 'PembroPlus' clinical trial.
A CTCA study found that the lung microbiome diversity in patients with lung cancer was characterized by a significant presence of Streptococcaceae family bacteria. This discovery may lead to new pharmacological cancer prevention strategies and improved treatment outcomes for lung cancer patients.
A new clinical trial, sponsored by Cancer Research And Biostatistics (CRAB), has been launched to test innovative treatments for lung cancer. The trial, which combines efforts from frontline treating oncologists and pharmaceutical companies, aims to improve patient outcomes and extend overall survival.
Dr. Walter Quan from Cancer Treatment Centers of America (CTCA) presents two new treatment options for previously-treated advanced cancer patients, showing major benefits with minimal side effects. The first treatment involves combination chemoimmunotherapy, while the second utilizes dose-dense outpatient intravenous Interleukin-2.
Glen J. Weiss, MD, presents studies on TSR-011, a potent ALK and TRK inhibitor, and Ki67, a measure of cell proliferation, in non-small cell lung cancer (NSCLC) tumors collected before chemotherapy and after surgery. These studies show preliminary clinical activity against various tumor types.
A study published in the Society of Integrative Oncology's Third International Conference found that antioxidant therapies do not hinder the effectiveness of radiation therapy for prostate cancer. The study, conducted by Cancer Treatment Centers of America, reviewed PSA levels of prostate cancer patients after receiving radiation thera...